Literature DB >> 28368261

Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.

Tamer M Fouad1, Angelica M Gutierrez Barrera2, James M Reuben3, Anthony Lucci4, Wendy A Woodward5, Michael C Stauder5, Bora Lim6, Sarah M DeSnyder7, Banu Arun2, Babiera Gildy7, Vicente Valero6, Gabriel N Hortobagyi2, Naoto T Ueno8.   

Abstract

In the absence of histological criteria that distinguish between inflammatory and non-inflammatory breast cancer, diagnosis of inflammatory breast cancer relies entirely on the existence of clinical criteria as outlined by the TNM classification. This classification restricts patients presenting with clinical criteria characteristic of inflammatory breast cancer to subcategory T4d, which immediately relegates all patients with non-metastatic inflammatory breast cancer to stage 3, regardless of tumour size or nodal spread. Patients who present with metastatic disease are consigned to stage 4, and the TNM classification does not distinguish patients on the basis of the presence of inflammatory criteria. Evidence by our group and others suggests that patients with inflammatory breast cancer have significantly reduced overall survival among those who present with distant metastasis at diagnosis (stage 4). In light of these results, this Personal View addresses whether the current TNM staging classification accurately represents a distinction between patients with inflammatory and those with non-inflammatory breast cancer.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28368261      PMCID: PMC6140765          DOI: 10.1016/S1470-2045(17)30192-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  28 in total

1.  Beyond palliative mastectomy in inflammatory breast cancer--a reassessment of margin status.

Authors:  L D Curcio; E Rupp; W L Williams; D Z Chu; K Clarke; T Odom-Maryon; J D Ellenhorn; G Somlo; L D Wagman
Journal:  Ann Surg Oncol       Date:  1999 Apr-May       Impact factor: 5.344

2.  Recommendation to revise the AJCC/UICC breast cancer staging system for inclusion of proven prognostic factors: ER/PR receptor status and HER2 neu.

Authors:  Vijayashree Murthy; Ronald S Chamberlain
Journal:  Clin Breast Cancer       Date:  2011-08-05       Impact factor: 3.225

Review 3.  The role of chemotherapy for metastatic breast cancer.

Authors:  K D Miller; G W Sledge
Journal:  Hematol Oncol Clin North Am       Date:  1999-04       Impact factor: 3.722

4.  Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study.

Authors:  Shaheenah Dawood; Naoto T Ueno; Vicente Valero; Wendy A Woodward; Thomas A Buchholz; Gabriel N Hortobagyi; Ana Maria Gonzalez-Angulo; Massimo Cristofanilli
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

5.  Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.

Authors:  Tamer M Fouad; Takahiro Kogawa; Diane D Liu; Yu Shen; Hiroko Masuda; Randa El-Zein; Wendy A Woodward; Mariana Chavez-MacGregor; Ricardo H Alvarez; Banu Arun; Anthony Lucci; Savitri Krishnamurthy; Gildy Babiera; Thomas A Buchholz; Vicente Valero; Naoto T Ueno
Journal:  Breast Cancer Res Treat       Date:  2015-05-29       Impact factor: 4.872

Review 6.  The role of inflammation in inflammatory breast cancer.

Authors:  Tamer M Fouad; Takahiro Kogawa; James M Reuben; Naoto T Ueno
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

7.  Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease.

Authors:  Massimo Cristofanilli; Vicente Valero; Aman U Buzdar; Shu-Wan Kau; Kristine R Broglio; Ana Maria Gonzalez-Angulo; Nour Sneige; Rabiul Islam; Naoto T Ueno; Thomas A Buchholz; Sonja E Singletary; Gabriel N Hortobagyi
Journal:  Cancer       Date:  2007-10-01       Impact factor: 6.860

8.  Inflammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features.

Authors:  Hamouda Boussen; Hatem Bouzaiene; Jamel Ben Hassouna; Amor Gamoudi; Farouk Benna; Khaled Rahal
Journal:  Semin Oncol       Date:  2008-02       Impact factor: 4.929

9.  Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database.

Authors:  Natasha M Rueth; Heather Y Lin; Isabelle Bedrosian; Simona F Shaitelman; Naoto T Ueno; Yu Shen; Gildy Babiera
Journal:  J Clin Oncol       Date:  2014-06-02       Impact factor: 44.544

View more
  31 in total

1.  Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.

Authors:  Naoko Matsuda; Xiaoping Wang; Bora Lim; Savitri Krishnamurthy; Ricardo H Alvarez; Jie S Willey; Charla A Parker; Juhee Song; Yu Shen; Jianhua Hu; Wenhui Wu; Nan Li; Gildy V Babiera; James L Murray; Banu K Arun; Abenaa M Brewster; James M Reuben; Michael C Stauder; Chad M Barnett; Wendy A Woodward; H T Carisa Le-Petross; Anthony Lucci; Sarah M DeSnyder; Debu Tripathy; Vicente Valero; Naoto T Ueno
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

2.  BRCA mutations in women with inflammatory breast cancer.

Authors:  Angelica M Gutierrez Barrera; Tamer M Fouad; Juhee Song; Rachel Webster; Nisreen Elsayegh; Anita L Wood; Atakan Demir; Jennifer K Litton; Naoto T Ueno; Banu K Arun
Journal:  Cancer       Date:  2017-10-17       Impact factor: 6.860

3.  Ganoderma lucidum enhances carboplatin chemotherapy effect by inhibiting the DNA damage response pathway and stemness.

Authors:  Ivette J Suárez-Arroyo; Ariana Acevedo-Díaz; Tiffany J Ríos-Fuller; Gabriela Ortiz-Soto; Ricardo Vallejo-Calzada; Jael Reyes-Chea; Gerónimo Maldonado-Martínez; Robert J Schneider; Michelle M Martínez-Montemayor
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

4.  Inflammatory Breast Cancer at the Extremes of Age.

Authors:  Taiwo Adesoye; Oluwatowo Babayemi; Lauren M Postlewait; Sarah M DeSnyder; Susie X Sun; Wendy A Woodward; Naoto T Ueno; Kelly K Hunt; Anthony Lucci; Mediget Teshome
Journal:  Ann Surg Oncol       Date:  2021-07-22       Impact factor: 5.344

5.  Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer.

Authors:  Evan N Cohen; Tamer M Fouad; Bang-Ning Lee; Banu K Arun; Diane Liu; Sanda Tin; Angelica M Gutierrez Barrera; Toshihide Miura; Iwao Kiyokawa; Jun Yamashita; Ricardo H Alvarez; Vicente Valero; Wendy A Woodward; Yu Shen; Naoto T Ueno; Massimo Cristofanilli; James M Reuben
Journal:  Breast Cancer Res Treat       Date:  2019-05-03       Impact factor: 4.872

6.  Current Surgical Management of Inflammatory Breast Cancer.

Authors:  Taiwo Adesoye; Anthony Lucci
Journal:  Ann Surg Oncol       Date:  2021-08-03       Impact factor: 5.344

Review 7.  Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2020-03-23

8.  In vitro vascularized tumor platform for modeling tumor-vasculature interactions of inflammatory breast cancer.

Authors:  Manasa Gadde; Caleb Phillips; Neda Ghousifam; Anna G Sorace; Enoch Wong; Savitri Krishnamurthy; Anum Syed; Omar Rahal; Thomas E Yankeelov; Wendy A Woodward; Marissa N Rylander
Journal:  Biotechnol Bioeng       Date:  2020-07-21       Impact factor: 4.530

9.  A usable model of "decathlon winner" cancer cells in triple-negative breast cancer: survival of resistant cancer cells in quiescence.

Authors:  Balraj Singh; Vanessa N Sarli; Laura J Washburn; Milan R Raythatha; Anthony Lucci
Journal:  Oncotarget       Date:  2018-01-25

Review 10.  Epigenetics in Inflammatory Breast Cancer: Biological Features and Therapeutic Perspectives.

Authors:  Flavia Lima Costa Faldoni; Cláudia Aparecida Rainho; Silvia Regina Rogatto
Journal:  Cells       Date:  2020-05-08       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.